Sirolimus

CHEMBL413 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

914.2 g/mol

LogP

6.0

Phase

4

Originally developed as a transplant anti-rejection drug, this medication suppresses the immune system and blocks a cellular growth pathway called mTOR. It is also used to treat certain rare kidney diseases, some hormone-sensitive cancers, and non-cancerous tumors that arise in genetic conditions such as tuberous sclerosis.

Molekularmasse

914,2000 g/mol

LogP

6,00

TPSA

195,00 Å²

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Age-Related Macular Degeneration Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Epilepsy Infectious Disease Melanoma Oncology Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain HIV/AIDS Hepatitis C Tuberculosis Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C

InChI

InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1

Molecular Formula

C51H79NO13

HBD / HBA

3 / 13

Rotierbare Bindungen

6

Schwere Atome

65

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

Originally developed as a transplant anti-rejection drug, this medication suppresses the immune system and blocks a cellular growth pathway called mTOR. It is also used to treat certain rare kidney diseases, some hormone-sensitive cancers, and non-cancerous tumors that arise in genetic conditions such as tuberous sclerosis.

Yes, Sirolimus is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL413. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5284616. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Sirolimus auf PillFYI

Struktur

Schnelldaten

Formel: C51H79NO13
Synonyme: 3

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.